Customer Support:
0300-9868966
Ruxolitinib cream, marketed under the brand name Opzelura, is a topical Janus kinase (JAK) inhibitor approved for the treatment of mild to moderate atopic dermatitis (eczema) and nonsegmental vitiligo in non-immunocompromised adults and children aged 12 years and older
| Availability | In Stock |
| Category : | Breast Enlargement |
| Product Size | 15MG |
| Made In | Imported |
| Payment Method | Cash on Delivery Bank Transfer |
| Delivery Time | 🚚 2–3 Days in Major Cities |
| Product Condition | Brand New • Sealed Pack |
Mild to moderate atopic dermatitis (eczema) in non-immunocompromised adults and pediatric patients aged 12 years and older, whose disease is not adequately controlled with topical prescription therapies or when those therapies are not advisable.
Nonsegmental vitiligo in adults and pediatric patients aged 12 years and older.
Ruxolitinib is a selective Janus kinase (JAK) inhibitor that targets JAK1 and JAK2 enzymes. By inhibiting these enzymes, ruxolitinib disrupts the JAK-STAT signaling pathway, which plays a key role in the inflammatory process and immune function. This action helps reduce inflammation in atopic dermatitis and may aid in repigmentation in vitiligo by modulating the immune response.
Apply a thin layer of ruxolitinib cream 1.5% to the affected areas twice daily.
For vitiligo, treatment may be applied to up to 10% of the body surface area.
The use of ruxolitinib cream should be limited to short-term and non-continuous chronic treatment.
Good product
Often Bought Together
